Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Inclusion Criteria: * Received kidney transplant at least 3 months prior to study enrollment * Receiving immunosuppressive regimen that includes MMF in combination with other immunosuppressive drugs * Receiving MMF for at least 1 month prior to enrollment Exclusion Criteria: * Patients with any known hypersensitivity against mycophenolic acid, mycophenolate sodium, mycophenolate mofetil or other components of the formulations (e.g. lactose; see also summary of product characteristics of EC-MPS) * If applicable, GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea) * Acute rejection \< 1 week prior to study enrollment Other protocol-defined inclusion/exclusion criteria may apply.